




PHARMACEUTICAL 2020

PUMA BIOTECHNOLOGY INC.
Rank 258 of 358





RealRate

PHARMACEUTICAL 2020

PUMA BIOTECHNOLOGY INC. Rank 258 of 358



The relative strengths and weaknesses of PUMA BIOTECHNOLOGY INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PUMA BIOTECHNOLOGY INC. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 84% points. The greatest weakness of PUMA BIOTECHNOLOGY INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 97% points.

The company's Economic Capital Ratio, given in the ranking table, is -20%, being 56% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	166,296
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	90,837
Liabilities, Non-Current	22,643
Other Assets	65,305
Other Compr. Net Income	74
Other Expenses	36,815
Other Liabilities	103,962
Other Net Income	-36,497
Other Revenues	272,260
Property and Equipment	3,304
Research and Development	132,851
Selling, General and Administrative Expense	141,692

Output Variable	Value in 1000 USD
Assets	234,905
Liabilities	217,442
Expenses	311,358
Revenues	272,260
Stockholders Equity	17,463
Net Income	-75,595
Comprehensive Net Income	-75,558
Economic Capital Ratio	-20%